WAYNE, Pa. and ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet need in immunology and rare genetic diseases, today announced business updates and year-end financial results for 2021.
“2021 was an important year for Avalo in that the Company produced compelling data for AVTX-002 in both acute and chronic inflammatory diseases. Furthermore, it positioned the Company to launch a placebo-controlled trial in NEA (AVTX-002), as well as two rare disease pivotal trials in 2022,” said Dr. Garry Neil, Chief Executive Officer of Avalo Therapeutics. “We are focused on the operational execution of these programs and their corresponding milestones, which have great potential to drive shareholder value in the coming year. We believe the recent pipeline prioritization will allow for greater focus on these most promising programs while also allowing for a reduction in cash burn.”
Business Updates:
Program Updates and Milestones:
2021 Financial Update:
As of December 31, 2021, Avalo had $54.6 million in cash and cash equivalents, representing a $35.7 million increase as compared to December 31, 2020. The increase was primarily driven by gross proceeds of approximately $72.2 million from underwritten public offerings and $35.0 million from a debt facility. Such increases were partially offset by operating expenditures, the majority of which were related to pipeline development.
Total operating expenses increased $8.0 million for the year ended December 31, 2021 as compared to the year ended December 31, 2020. The increase in operating expenses was largely driven by a $27.6 million increase in research and development expenses to support our maturing pipeline and a $4.4 million increase in general and administrative expenses, partially offset by a $25.5 million reduction in acquired in-process research and development expense as this charge in 2020 did not repeat.
Consolidated Balance Sheets
(In thousands, except share and per share data)
| December 31, | ||||||||
| 2021 | 2020 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 54,585 | $ | 18,919 | ||||
| Accounts receivable, net | 1,060 | 2,177 | ||||||
| Other receivables | 3,739 | 2,208 | ||||||
| Inventory, net | 38 | 3 | ||||||
| Prepaid expenses and other current assets | 2,372 | 2,660 | ||||||
| Restricted cash, current portion | 51 | 38 | ||||||
| Total current assets | 61,845 | 26,005 | ||||||
| Property and equipment, net | 2,695 | 1,607 | ||||||
| Other long-term asset | 1,000 | — | ||||||
| Intangible assets, net | 38 | 1,585 | ||||||
| Goodwill | 14,409 | 14,409 | ||||||
| Restricted cash, net of current portion | 227 | 149 | ||||||
| Total assets | $ | 80,214 | $ | 43,755 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,369 | $ | 2,574 | ||||
| Accrued expenses and other current liabilities | 16,519 | 11,310 | ||||||
| Income taxes payable | — | — | ||||||
| Current liabilities of discontinued operations | — | 1,341 | ||||||
| Total current liabilities | 19,888 | 15,225 | ||||||
| Notes payable, net | 32,833 | — | ||||||
| Royalty obligation | 2,000 | 2,000 | ||||||
| Deferred tax liability, net | 113 | 90 | ||||||
| Other long-term liabilities | 2,298 | 1,878 | ||||||
| Total liabilities | 57,132 | 19,193 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock—$0.001 par value; 200,000,000 shares authorized at December 31, 2021 and 2020; 112,794,203 and 75,004,127 shares issued and outstanding at December 31, 2021 and 2020, respectively | 113 | 75 | ||||||
| Preferred stock—$0.001 par value; 5,000,000 shares authorized at December 31, 2021 and 2020; 0 and 1,257,143 shares issued and outstanding at December 31, 2021 and 2020, respectively | — | 1 | ||||||
| Additional paid-in capital | 285,135 | 202,276 | ||||||
| Accumulated deficit | (262,166 | ) | (177,790 | ) | ||||
| Total stockholders’ equity | 23,082 | 24,562 | ||||||
| Total liabilities and stockholders’ equity | $ | 80,214 | $ | 43,755 | ||||
The consolidated balance sheets as of December 31, 2021 and 2020 have been derived from the audited financial statements, but do not include all of the information and footnotes required by accounting principles accepted in the United States for complete financial statements.
Consolidated Statements of Operations
(In thousands, except per share data)
| Year Ended December 31, | ||||||||
| 2021 | 2020 | |||||||
| Revenues: | ||||||||
| Product revenue, net | $ | 4,773 | $ | 6,699 | ||||
| License revenue | 625 | — | ||||||
| Total revenues, net | 5,398 | 6,699 | ||||||
| Operating expenses: | ||||||||
| Cost of product sales | 1,491 | 300 | ||||||
| Research and development | 59,835 | 32,193 | ||||||
| Acquired in-process research and development | — | 25,549 | ||||||
| General and administrative | 21,832 | 17,418 | ||||||
| Sales and marketing | 2,826 | 2,341 | ||||||
| Amortization expense | 1,548 | 1,741 | ||||||
| Total operating expenses | 87,532 | 79,542 | ||||||
| (82,134 | ) | (72,843 | ) | |||||
| Other (expense) income: | ||||||||
| Change in fair value of Investment in Aytu | — | 5,208 | ||||||
| Other (expense) income, net | (20 | ) | 409 | |||||
| Interest (expense) income, net | (2,391 | ) | 49 | |||||
| Total other (expense) income, net from continuing operations | (2,411 | ) | 5,666 | |||||
| Loss from continuing operations before income taxes | (84,545 | ) | (67,177 | ) | ||||
| Income tax benefit | (196 | ) | (2,793 | ) | ||||
| Loss from continuing operations | $ | (84,349 | ) | $ | (64,384 | ) | ||
| (Loss) income from discontinued operations | (27 | ) | 884 | |||||
| Net loss | $ | (84,376 | ) | $ | (63,500 | ) | ||
| Net (loss) income per share of common stock, basic and diluted: | ||||||||
| Continuing operations | $ | (0.83 | ) | $ | (0.87 | ) | ||
| Discontinued operations | 0.00 | 0.01 | ||||||
| Net loss per share of common stock, basic and diluted | $ | (0.83 | ) | $ | (0.86 | ) | ||
| Net (loss) income per share of preferred stock, basic and diluted: | ||||||||
| Continuing operations | $ | (4.15 | ) | $ | (4.38 | ) | ||
| Discontinued operations | 0.00 | 0.06 | ||||||
| Net loss per share of preferred stock, basic and diluted | $ | (4.15 | ) | $ | (4.32 | ) | ||
The consolidated statements of operations for the years ended December 31, 2021 and 2020 have been derived from the audited financial statements, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.
About Avalo Therapeutics
Avalo Therapeutics is a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases. The Company has built a diverse portfolio of innovative therapies to deliver meaningful medical impact for patients in urgent need. The Company’s clinical candidates commonly have a proven mechanistic rationale, biomarkers and/or an established proof-of-concept to expedite and increase the probability of success.
For more information about Avalo, please visit www.avalotx.com.
Forward-Looking Statements
This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: the future financial and operational outlook; the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Avalo’s management but are subject to significant risks and uncertainties, including: drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; reliance on key personnel, including as a result of recent management changes; regulatory risks; Avalo’s cash position and the potential need for it to raise additional capital; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic and tensions in Ukraine; and those other risks detailed in Avalo’s filings with the SEC. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For media and investor inquiries
Chris Brinzey
Westwicke, an ICR Company
Chris.brinzey@westwicke.com
339-970-2843
or
Maxim Jacobs, CFA
Vice President, Investor Relations
Avalo Therapeutics
mjacobs@avalotx.com
610-254-4201
Financials for Fiscal Year 2024 Ended March 31, 2024 will be released on July 1,…
Aveva's Renaming Reflects Expanded Public Health Technology Offerings, Signals Next Phase of Growth VIENNA, Va.,…
RAMAT GAN, Israel, June 26, 2024 /PRNewswire/ -- Medasense, a global leader in pain monitoring…
BOSTON, June 26, 2024 /PRNewswire/ -- Refractive lenses are one of humanity's oldest and most…
WESTFORD, Mass., June 26, 2024 /PRNewswire/ -- According to SkyQuest, the Blockchain Technology in Healthcare Market…
BELMONT, Mich., June 26, 2024 /PRNewswire/ -- AvaSure, a market leader in acute virtual care, announced…